U.S. Markets closed

  • S&P Futures

    4,121.75
    -2.75 (-0.07%)
     

  • Dow Futures

    32,731.00
    -6.00 (-0.02%)
     

  • Nasdaq Futures

    13,017.00
    -14.50 (-0.11%)
     

  • Russell 2000 Futures

    1,912.90
    -1.70 (-0.09%)
     

  • Crude Oil

    90.36
    -0.14 (-0.15%)
     

  • Gold

    1,810.30
    -2.00 (-0.11%)
     

  • Silver

    20.50
    +0.02 (+0.11%)
     

  • EUR/USD

    1.0220
    +0.0002 (+0.0204%)
     

  • 10-Yr Bond

    2.7970
    +0.0320 (+1.16%)
     

  • Vix

    21.77
    +0.48 (+2.25%)
     

  • GBP/USD

    1.2082
    +0.0005 (+0.0447%)
     

  • USD/JPY

    135.0510
    -0.0650 (-0.0481%)
     

  • BTC-USD

    22,857.05
    -920.48 (-3.87%)
     

  • CMC Crypto 200

    530.74
    -26.61 (-4.77%)
     

  • FTSE 100

    7,488.15
    +5.78 (+0.08%)
     

  • Nikkei 225

    27,784.38
    -215.62 (-0.77%)
     

LAMEA Peptide Therapeutics Market Report 2022: Annual Growth of 12.5% Expected Through 2028

·3 min read

DUBLIN, Aug. 5, 2022 /PRNewswire/ -- The "LAMEA Peptide Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Innovative and Generic), By Route of Administration, By Synthesis Technology, By Type of Manufacturers, By Application, By Country and Growth Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.

Research_and_Markets_Logo
Research_and_Markets_Logo

The Latin America, Middle East and Africa Peptide Therapeutics Market is expected to witness market growth of 12.5% CAGR during the forecast period (2022-2028).

O-glycosylation takes place in threonine or serine residues, where the oxygen molecule on the side chain forms an ether bond with the carbohydrate. Chemical glycosylation is a type of non-natural glycosylation that involves the binding of carbohydrate units to distinct amino acid residues at the peptide's N-terminus.

Chemo-enzymatic glycosylation is another method of glycosylation that involves the use of enzymes. This approach is employed in the synthesis of complicated chemicals. Glycol-peptides and glycoproteins can be synthesized via chemical and chemo-enzymatic techniques. Cyclization can also be utilized to reduce proteolytic degradation and extend half-life by stiffening the peptide shape to prevent enzymatic cleavage.

AIDS, tuberculosis, malaria, gastroenteritis, and hypertension are the most common health concerns in Africa. According to the National Library of Medicines, hypertension affects nearly 20% of the adult population. Renal illness, particularly glomerular disease, is more common in Africa, and it appears to be more severe than in Western countries. The nephrotic syndrome is the most common manner of presentation, with onset between the ages of five and eight years. Renal-related symptoms account for 2 to 3% of overall medical admissions in tropical nations, with glomerulonephritides accounting for the bulk.

In all African countries, there are no accurate statistics on ESRD. The South African Dialysis and Transplant Registry (SADTR) statistics represent patients who have been approved for renal replacement therapy (RRT) rather than the etiology of chronic renal failure (CRF), as public sector state facilities is expected to only provide RRT to patients who are transplant candidates.

The Brazil market dominated the LAMEA Peptide Therapeutics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $1,273.3 million by 2028. The Argentina market is poised to grow at a CAGR of 13.1% during (2022-2028). Additionally, The UAE market is expected to display a CAGR of 12.2% during (2022-2028).


Scope of the Study
Market Segments Covered in the Report:
By Type

  • Innovative

  • Generic

By Route of Administration

  • Parenteral Route

  • Pulmonary

  • Mucosal

  • Oral Route

  • Others

By Synthesis Technology

  • Liquid Phase Peptide Synthesis (LPPS)

  • Solid Phase Peptide Synthesis (SPPS)

  • Hybrid Technology

By Type of Manufacturers

  • In-house

  • Outsourced

By Application

  • Metabolic

  • Cardiovascular Disorder

  • GIT & Renal

  • Antiinfection & Dermatology

  • Respiratory

  • Central Nervous System

  • Cancer

  • Pain

  • Others

By Country

  • Brazil

  • Argentina

  • UAE

  • Saudi Arabia

  • South Africa

  • Nigeria

  • Rest of LAMEA

Key Market Players

  • Eli Lilly And Company

  • AstraZeneca PLC

  • Teva Pharmaceuticals Industries Ltd.

  • Novartis AG

  • Pfizer, Inc.

  • Sanofi S.A.

  • GlaxoSmithKline PLC

  • Takeda Pharmaceutical Company Limited

  • Lonza Group AG

  • Amgen, Inc.

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview

Chapter 3. Competition Analysis - Global

Chapter 4. LAMEA Peptide Therapeutics Market by Type

Chapter 5. LAMEA Peptide Therapeutics Market by Route of Administration

Chapter 6. LAMEA Peptide Therapeutics Market by Synthesis Technology

Chapter 7. LAMEA Peptide Therapeutics Market by Type of Manufacturers

Chapter 8. LAMEA Peptide Therapeutics Market by Application

Chapter 9. LAMEA Peptide Therapeutics Market by Country

Chapter 10. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/msf289

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

 

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

 

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

 

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/lamea-peptide-therapeutics-market-report-2022-annual-growth-of-12-5-expected-through-2028--301600712.html

SOURCE Research and Markets

Recommended Stories

  • CorMedix Slapped With Second FDA Rejection For DefenCath

    CorMedix Inc (NASDAQ: CRMD) received a second Complete Response Letter (CRL) from the FDA for DefenCath, developed as a catheter lock solution to reduce catheter-related bloodstream infections in patients with renal failure receiving chronic hemodialysis via a central venous catheter. The letter states that DefenCath cannot be approved until deficiencies recently conveyed to the contract manufacturing organization and the supplier of the active pharmaceutical ingredient heparin during inspection

  • These 2 Penny Stocks Are Poised for a Big Rally, Says Oppenheimer

    Does high risk mean high reward? Not necessarily, so say the pros on Wall Street. Specifically citing penny stocks, or stocks that trade for less than $5 per share, analysts advise caution as these names might still be in the early innings, or it could be that they face an uphill battle that is just too steep. Luring investors with their bargain price tags, these stocks might be up against overpowering headwinds or have weak fundamentals. However, analysts argue there are early-stage companies t

  • U.S. OKs plan to stretch monkeypox vaccine supply by using smaller doses

    U.S. health officials on Tuesday authorized a plan to stretch the nation’s limited supply of monkeypox vaccine by giving people just one-fifth the usual dose, citing research suggesting that the reduced amount is about as effective.

  • Karuna’s Schizophrenia-Trial Data Are ‘Best Case Scenario’ for the Biotech Stock

    Analysts said the results were strong enough that the drug could be the go-to treatment once it is approved.

  • FDA grants emergency authorization allowing monkeypox vaccine by intradermal injection

    The Food and Drug Administration granted an emergency authorization that allows healthcare providers to give out the Jynneos monkeypox vaccine to adults intradermally instead of subcutaneously. Injecting the vaccine into an upper layer of the skin is expected to allow more doses of the vaccine developed by Bavarian Nordic to be made available to the public during the public health emergency. "Given the continued spread of the monkeypox virus at a rate outpacing the availability of our current va

  • A COVID-vaccine maker received $1.6 billion in Operation Warp Speed funding. It’s administered just 7,300 shots in the U.S.

    Novavax’s jab only gained FDA approval in July and entered a saturated COVID-vaccine market.

  • Novavax tumbles 30% as waning COVID-19 vaccine demand hits outlook

    Demand for its vaccine is also waning in the United States, where it was authorized for use among adults last month and was expected to be preferred by the skeptics of messenger RNA-based shots from Moderna Inc and Pfizer Inc. But only 7,381 Novavax vaccine doses have been administered so far in the country and Chief Executive Stanley Erck said that its late launch could have hampered demand. Novavax shares fell 29.6% to close down at $40.28 a share.

  • Covid Vaccine Maker Novavax Tumbles After Cutting Annual Sales Forecast 50%

    (Bloomberg) -- Novavax Inc. shares had their biggest loss in more than three years as the drugmaker slashed its 2022 revenue forecast late Monday on disappointing demand for its Covid-19 vaccine that trailed competitors getting to market.Most Read from BloombergTrump Under Intense Legal Scrutiny After FBI Searches Mar-a-LagoTrump Search Was Unprecedented, But Records Case Will Be ToughUK Plans for Blackouts in January in Emergency Energy PlanHome Inventory Soars at Record Rate With US Buyers Pul

  • CinCor Pharma Shares Trade Higher After Positive Data From Hypertension Drug

    CinCor Pharma Inc (NASDAQ: CINC) has announced topline results from Phase 2 BrigHtn trial evaluating baxdrostat for treatment-resistant hypertension. Results showed baxdrostat met its primary endpoint and achieved a statistically significant placebo-adjusted reduction in systolic blood pressure (SBP), including 11 mmHg at 2 mg. BrigHtn successfully met its primary endpoint, demonstrating a statistically significant change from baseline in mean seated SBP versus placebo for the 2 mg and 1 mg dose

  • Is Pfizer Stock A Buy As It Preps $5.4 Billion Foray Into Sickle Cell Disease?

    Is Pfizer stock a buy after the company announced its $5.4 billion plan to buy Global Blood Therapeutics? Is PFE stock a buy right now?

  • Months after celebrating its first exit, CinRx invests $10M in newest portfolio company

    A Cincinnati-based portfolio company that celebrated a massive exit earlier this year has invested millions to accelerate development of a new treatment option for people with Type 1 diabetes.

  • The U.S. has declared monkeypox an emergency. It’s about time | Opinion

    As monkeypox cases in the United States climbed to more than 7,100, Health and Human Services Secretary Xavier Becerra declared the outbreak a public health emergency. It’s long past time.

  • Chronic cough drug developer plays it cool as it seeks cash for late-stage study

    Can the "ice cream receptor" reduce chronic cough? A small biotech thinks so, if it can get enough money to pay for a late-stage clinical trial.

  • Medicare Drug Costs to Be Capped at $2,000 a Year in Inflation Reduction Act

    The bill also grants the healthcare program for seniors the right to negotate drug prices for the first time and will penalize drug makers that increase prices for their medicines by more than the rate of inflation.

  • Pfizer Agrees to $5.4 Billion Deal for Global Blood Therapeutics

    Pfizer has agreed to buy Global Blood Therapeutics for $5.4 billion, a deal that will give the big drugmaker a foothold in the treatment of sickle-cell disease.

  • Abortion bans complicate access to drugs for cancer, arthritis, even ulcers

    Becky Hubbard, 46, has decided to get sterilized so that she can go back on the only medication that has relieved her disabling pain from rheumatoid arthritis for the last eight years. Soon after the Supreme Court struck down Roe v. Wade, the Tennessee woman said she got an ultimatum from her rheumatologist. If she wanted to stay on the treatment of choice for her condition, a drug called methotrexate, she was told she had to go on birth control despite her age and history of infertility.Subscri

  • FDA Approves Expanded Use For Bayer's Prostate Cancer Drug

    The FDA approved Bayer AG's (OTC: BAYRY) supplemental marketing application for Nubeqa (darolutamide) with docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on the results of Phase 3 ARASENS trial that demonstrated a reduction in the risk of death by 32% in Nubeqa plus androgen deprivation therapy and docetaxel compared to ADT and docetaxel. Nubeqa plus ADT and docetaxel also resulted in a statistically significant delay in time to pain progression. The re

  • BioNTech expects Omicron-adapted vaccine deliveries as soon as October

    BERLIN (Reuters) -BioNTech expects to begin deliveries of two Omicron-adapted vaccines as soon as October, which will help spur demand in the fourth quarter, the German biotech firm said on Monday as it reaffirmed its vaccine-revenue forecast for the year. However, booster campaigns using upgraded shots specifically targeting the Omicron variant are expected to increase demand in autumn. Pending regulatory approval, BioNTech said, both of its adapted vaccines would be available in time for the campaigns.

  • There’s a Monkeypox Treatment Drug Approved by the FDA—Here’s What We Know

    Tecovirimat (also known as Tpoxx) is the only available monkeypox treatment in the U.S., and it’s FDA approved. However, it’s hard to get. Experts explain how it works.

  • Climate change puts Lyme disease in focus for France's Valneva after COVID blow

    With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva is betting big on a vaccine as it looks beyond disappointing sales of its COVID shot. Although Valneva secured European Union and British regulatory approval, both walked away from contracts worth more than a billion dollars combined, wiping nearly 40% off the value of Valneva's share price in the past six months. But unlike the fierce competition with major international drugmakers such as Pfizer, Moderna and AstraZeneca to roll out vaccines to tackle the coronavirus pandemic, there are no established rivals for either Lyme disease or Chikungunya.